| Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGFβ, in advanced solid tumors J Strauss, CR Heery, J Schlom, RA Madan, L Cao, Z Kang, E Lamping, ... Clinical Cancer Research 24 (6), 1287-1295, 2018 | 340 | 2018 |
| Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial CR Heery, G O'Sullivan-Coyne, RA Madan, L Cordes, A Rajan, ... The Lancet Oncology 18 (5), 587-598, 2017 | 302 | 2017 |
| Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations F Karzai, D VanderWeele, RA Madan, H Owens, LM Cordes, A Hankin, ... Journal for immunotherapy of cancer 6, 1-12, 2018 | 245 | 2018 |
| Phase I study of cabozantinib and nivolumab alone or with ipilimumab for advanced or metastatic urothelial carcinoma and other genitourinary tumors AB Apolo, R Nadal, DM Girardi, SA Niglio, L Ley, LM Cordes, ... Journal of Clinical Oncology 38 (31), 3672, 2020 | 102 | 2020 |
| Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies J Strauss, ME Gatti-Mays, BC Cho, A Hill, S Salas, E McClay, JM Redman, ... Journal for immunotherapy of cancer 8 (2), 2020 | 90 | 2020 |
| Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial AB Apolo, R Nadal, Y Tomita, NN Davarpanah, LM Cordes, SM Steinberg, ... The Lancet Oncology 21 (8), 1099-1109, 2020 | 68 | 2020 |
| Endocrine‐related adverse events related to immune checkpoint inhibitors: Proposed algorithms for management J Del Rivero, LM Cordes, J Klubo‐Gwiezdzinska, RA Madan, LK Nieman, ... The Oncologist 25 (4), 290-300, 2020 | 68 | 2020 |
| Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with with metastatic urothelial … RM Nadal, A Mortazavi, M Stein, SK Pal, NN Davarpanah, HL Parnes, ... Journal of Clinical Oncology 36 (6_suppl), 515-515, 2018 | 68 | 2018 |
| Phase I study of a poxviral TRICOM-based vaccine directed against the transcription factor brachyury CR Heery, C Palena, S McMahon, RN Donahue, LM Lepone, I Grenga, ... Clinical Cancer Research 23 (22), 6833-6845, 2017 | 63 | 2017 |
| A phase I dose-escalation trial of BN-CV301, a recombinant poxviral vaccine targeting MUC1 and CEA with costimulatory molecules ME Gatti-Mays, J Strauss, RN Donahue, C Palena, J Del Rivero, ... Clinical Cancer Research 25 (16), 4933-4944, 2019 | 51 | 2019 |
| A phase I trial using a multitargeted recombinant adenovirus 5 (CEA/MUC1/Brachyury)‐based immunotherapy vaccine regimen in patients with advanced cancer ME Gatti‐Mays, JM Redman, RN Donahue, C Palena, RA Madan, ... The oncologist 25 (6), 479-e899, 2020 | 47 | 2020 |
| Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer HA Sater, JL Marté, RN Donahue, B Walter-Rodriguez, CR Heery, ... Journal for ImmunoTherapy of Cancer 8 (1), 2020 | 46 | 2020 |
| A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population. F Karzai, RA Madan, H Owens, A Couvillon, A Hankin, M Williams, ... Journal of Clinical Oncology 36 (6_suppl), 163-163, 2018 | 41 | 2018 |
| Avelumab in metastatic castration-resistant prostate cancer (mCRPC). F Fakhrejahani, RA Madan, WL Dahut, M Bilusic, F Karzai, LM Cordes, ... Journal of Clinical Oncology 35 (15_suppl), 5037-5037, 2017 | 36 | 2017 |
| Safety and activity of M7824, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with HPV associated cancers. J Strauss, ME Gatti-Mays, J Redman, RA Madan, E Lamping, M Manu, ... Journal of Clinical Oncology 36 (15_suppl), 3007-3007, 2018 | 32 | 2018 |
| Avelumab: a new standard for treating metastatic Merkel cell carcinoma M Baker, L Cordes, I Brownell Expert Review of Anticancer Therapy 18 (4), 319-326, 2018 | 30 | 2018 |
| Pharmacokinetic profile and receptor occupancy of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in a phase I, open-label, dose escalation trial in patients with … CR Heery, GH O'Sullivan Coyne, JL Marte, H Singh, LM Cordes, ... Journal of Clinical Oncology 33 (15_suppl), 3055-3055, 2015 | 29 | 2015 |
| Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration‐resistant prostate cancer RA Madan, FH Karzai, YM Ning, BA Adesunloye, X Huang, N Harold, ... BJU international 118 (4), 590-597, 2016 | 28 | 2016 |
| A phase I study of cabozantinib plus nivolumab (CaboNivo) and cabonivo plus ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic (m) urothelial carcinoma (UC … AB Apolo, A Mortazavi, MN Stein, NN Davarpanah, RM Nadal, HL Parnes, ... Journal of Clinical Oncology 35 (15_suppl), 4562-4562, 2017 | 27 | 2017 |
| Sequential prostate magnetic resonance imaging in newly diagnosed high-risk prostate cancer treated with neoadjuvant enzalutamide is predictive of therapeutic response F Karzai, SM Walker, S Wilkinson, RA Madan, JH Shih, MJ Merino, ... Clinical Cancer Research 27 (2), 429-437, 2021 | 26 | 2021 |
